Bioneedles™ as vaccine carriers

Vaccine

Volumn 26, Issue 19, 2008, Pages 2389-2397

  Hirschberg, Hoang J H B ^a   van de Wijdeven, Gijsbert G P ^b   Kelder, Annemarie B ^a   van den Dobbelsteen, Germie P J M ^a   Kersten, Gideon F A ^a  

^a NETHERLANDS VACCINE INSTITUTE   (Netherlands)

^b Bioneedle Technologies Group BV   (Netherlands)

Author keywords

Bioneedles; Tetanus toxoid; Trehalose; Vaccine

Indexed keywords

ALUMINUM PHOSPHATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; TETANUS TOXOID; TREHALOSE; ALUMINUM DERIVATIVE; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; PHOSPHATE; TETANUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGENICITY; ARTICLE; BIODEGRADABLE IMPLANT; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG STABILITY; FREEZE DRYING; IMMUNIZATION; IMMUNOGENICITY; LIQUID; MONOTHERAPY; MOUSE; NEEDLE; NONHUMAN; PRIORITY JOURNAL; SHELF LIFE; SYRINGE; TEMPERATURE DEPENDENCE; THERMOSTABILITY; ANIMAL; BLOOD; COMPARATIVE STUDY; HEAT; IMMUNOLOGY; METHODOLOGY; TIME; VACCINATION;

ABSORBABLE IMPLANTS; ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; DRUG STABILITY; HEAT; MICE; PHOSPHATES; TETANUS ANTITOXIN; TETANUS TOXOID; TIME FACTORS; VACCINATION;

EID: 42649083648     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.067     Document Type: Article

References (40)

1. Kermode M. Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot Int 19 1 (2004) 95-103
2. Kane A., Lloyd J., Zaffran M., Simonsen L., and Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 77 10 (1999) 801-807
3. Weir E., and Hatch K. Preventing cold chain failure: vaccine storage and handling. CMAJ 171 9 (2004) 1050
4. Das P. Revolutionary vaccine technology breaks the cold chain. Lancet Infect Dis 4 12 (2004) 719
5. Jacobson R.M., Swan A., Adegbenro A., Ludington S.L., Wollan P.C., and Poland G.A. Making vaccines more acceptable - methods to prevent and minimize pain and other common adverse events associated with vaccines. Vaccine 19 17-19 (2001) 2418-2427
6. Nir Y., Paz A., Sabo E., and Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 68 3 (2003) 341-344
7. Igietseme J.U., Eko F.O., He Q., and Black C.M. Combination vaccines: design strategies and future trends. Expert Rev Vaccines 5 6 (2006) 739-745
8. Azad N., and Rojanasakul Y. Vaccine delivery - current trends and future. Curr Drug Deliv 3 2 (2006) 137-146
9. Giudice E.L., and Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev (2006) 68-89
10. Kersten G., and Hirschberg H. Needle-free vaccine delivery. Expert Opin Drug Deliv 4 5 (2007) 459-474
11. Mitragotri S. Immunization without needles. Nat Rev Immunol (2005) 905-916
12. O'Hagan D.T., and Rappuoli R. Novel approaches to vaccine delivery. Pharm Res 21 9 (2004) 1519-1530
13. O'Hagan D.T. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord 1 3 (2001) 273-286
14. Russell-Jones G.J. Oral vaccine delivery. J Control Release 65 1-2 (2000) 49-54
15. Davis S.S. Nasal vaccines. Adv Drug Deliv Rev 51 1-3 (2001) 21-42
16. Illum L., and Davis S.S. Nasal vaccination: a non-invasive vaccine delivery method that holds great promise for the future. Adv Drug Deliv Rev 51 1-3 (2001) 1-3
17. Agerso H., Moller-Pedersen J., Cappi S., Thomann P., Jesussek B., and Senderovitz T. Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. J Clin Pharmacol 42 11 (2002) 1262-1268
18. Baxter J., and Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Expert Rev Med Devices 3 5 (2006) 565-574
19. Williams J., Fox-Leyva L., Christensen C., Fisher D., Schlicting E., Snowball M., et al. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 18 18 (2000) 1939-1943
20. Chen D., Maa Y.F., and Haynes J.R. Needle-free epidermal powder immunization. Expert Rev Vaccines 1 3 (2002) 265-276
21. Osorio J.E., Zuleger C.L., Burger M., Chu Q., Payne L.G., and Chen D. Immune responses to hepatitis B surface antigen following epidermal powder immunization. Immunol Cell Biol 81 1 (2003) 52-58
22. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., and Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 6 12 (2000) 1403-1406
23. Partidos C.D. Antigens onto bare skin: a 'painless' paradigm shift in vaccine delivery. Expert Opin Biol Ther 3 6 (2003) 895-902
24. Partidos C.D., Beignon A.S., Mawas F., Belliard G., Briand J.P., and Muller S. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 21 7-8 (2003) 776-780
25. Barry B.W. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14 2 (2001) 101-114
26. Gill H.S., and Prausnitz M.R. Coated microneedles for transdermal delivery. J Control Release (2006) 227-237
27. Martanto W., Davis S.P., Holiday N.R., Wang J., Gill H.S., and Prausnitz M.R. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 21 6 (2004) 947-952
28. Partidos C.D., and Muller S. Decision-making at the surface of the intact or barrier disrupted skin: potential applications for vaccination or therapy. Cell Mol Life Sci (2005) 1418-1424
29. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 56 5 (2004) 581-587
30. Widera G., Johnson J., Kim L., Libiran L., Nyam K., Daddona P.E., et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine (2005) 1653-1664
31. van de Wijdeven G.G. Development and assessment of mini projectiles as drug carriers. J Control Release 85 1-3 (2002) 145-162
32. Hendriksen C.F., van der Gun J.W., Marsman F.R., and Kreeftenberg J.G. The use of the in vitro toxin binding inhibition (ToBI) test for the estimation of the potency of tetanus toxoid. Biologicals 19 1 (1991) 23-29
33. Gribbon E.M., Sen S.D., Roser B.J., and Kampinga J. Stabilisation of vaccines using trehalose (Q-T4) technology. Dev Biol Stand 87 (1996) 193-199
34. Aguado M., Joda L., Lloyd J., and Lambert P. WHO Drug Information 12 2 (1998) 67-99
35. Diminsky D., Moav N., Gorecki M., and Barenholz Y. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18 1-2 (1999) 3-17
36. Maa Y.F., Zhao L., Payne L.G., and Chen D. Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application. J Pharm Sci 92 2 (2003) 319-332
37. Chang L.L., Shepherd D., Sun J., Ouellette D., Grant K.L., Tang X.C., et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix?. J Pharm Sci 94 7 (2005) 1427-1444
38. Kawai K., and Suzuki T. Stabilizing effect of four types of disaccharide on the enzymatic activity of freeze-dried lactate dehydrogenase: step by step evaluation from freezing to storage. Pharm Res (2007) 1883-1890
39. Zhang F., Liang Z., Matsuki N., Van K.L., Joyce S., Wakeland E.K., et al. A murine locus on chromosome 18 controls NKT cell homeostasis and Th cell differentiation. J Immunol 171 9 (2003) 4613-4620
40. Nagabhushanam V., and Cheers C. Non-major histocompatibility complex control of antibody isotype and Th1 versus Th2 cytokines during experimental infection of mice with Mycobacterium avium. Infect Immun 69 3 (2001) 1708-1713